Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania. Show more

1500 Liberty Ridge Drive, Wayne, PA, 19087, United States

https://www.avalotx.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

976.6M

52 Wk Range

$9.54 - $24.27

Previous Close

$18.21

Open

$17.92

Volume

177,029

Day Range

$17.58 - $18.04

Enterprise Value

657M

Cash

400.3M

Avg Qtr Burn

-19.99M

Insider Ownership

1.69%

Institutional Own.

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
AVTX-803 (CERC-803) Details Leukocyte Adhesion Deficiency Type II	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-009 Details Hidradenitis suppurativa, Autoimmune disease	Phase 3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/ AVTX-002 (CERC-002) Details COVID-19	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/AVTX-002 (CERC-002) Details Asthma	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Quisovalimab/ AVTX-002 (CERC-002) Details Crohns disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-007 (CERC-007) Details Multiple myeloma, Adult Onset Still's Disease	Phase 1b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-010 (IL-1β Antibody) Details Hidradenitis Suppurativa, Inflammatory Disorders	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-801 (CERC-801) Details Metabolic disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-006 (CERC-006) Details Lymphatic malformations	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
AVTX-802 (CERC-802) Details Metabolic disorder, Rare genetic disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.